Join
Live feed
·
NEWSReleasevia Quantisnow
Biocept Inc. logo

Enrollment Completed In The Feasibility Phase Of The FORESEE Clinical Trial With Biocept's CNSide Assay To Evaluate Patients With Leptomeningeal Metastases

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIOC (Biocept Inc.) and more on Quantisnow.